Citius Oncology CTOR
NASDAQ CTOR
$0.57 -0.13 (-18.54%)
As of: Oct 23, 2026 · 3:57 PM EDT

Citius Oncology (CTOR) Amortization of Deferred Charges (2026)

Updated

Analysis

Citius Oncology (CTOR) Amortization of Deferred Charges (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Citius Oncology 62.31 Mn 31.89 Mn 1.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 179,492.00
API Access

Citius Oncology Amortization of Deferred Charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-of-deferred-charges&ticker=CTOR&period=max&api_key=YOUR_API_KEY